Capital Impact Advisors, LLC Fate Therapeutics Inc Transaction History

Capital Impact Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $21,043 - $29,134	4,421 Added 10.7%	45,738 $217,000
Q1 2023 May 23, 2023	BUY	$4.24 - $11.12 $96,926 - $254,203	22,860 Added 123.86%	41,317 $235,000
Q4 2022 Feb 14, 2023	SELL	$9.86 - $23.83 $17,905 - $43,275	-1,816 Reduced 8.96%	18,457 $186,000
Q3 2022 Nov 21, 2022	BUY	$21.04 - $36.06 $78,836 - $135,116	3,747 Added 22.67%	20,273 $408,000
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $41,302 - $98,471	-2,323 Reduced 12.32%	16,526 $410,000
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $256,615 - $521,361	8,649 Added 84.79%	18,849 $731,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $487,968 - $656,268	10,200 New	10,200 $597,000
Q1 2021 May 18, 2021	SELL	$72.16 - $117.4 $2.31 Million - $3.76 Million	-32,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$38.09 - $100.95 $1.22 Million - $3.23 Million	32,000 New	32,000 $2.91 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.